• About us
    • History
    • Advantages
    • IPHAR company group
    • Board of directors
    • Scientific council
  • Investment projects
    • Preclinical stage
    • Clinical stage
    • Information for investors
  • Services
    • Drug development
    • Pharmaceutical technology
    • Pharmaceutical development
    • Preclinical trials
    • Pharmaceutical and
      pharmacokinetic analysis
    • Clinical trials
  • Video
  • Skolkovo Collective Use Center
  • Contacts
  • Job offerings
  • RURU
  • About us
    • History
    • Advantages
    • IPHAR company group
    • Board of directors
    • Scientific council
  • Investment projects
    • Preclinical stage
    • Clinical stage
    • Information for investors
  • Services
    • Drug development
    • Pharmaceutical technology
    • Pharmaceutical development
    • Preclinical trials
    • Pharmaceutical and
      pharmacokinetic analysis
    • Clinical trials
  • Video
  • Skolkovo Collective Use Center
  • Contacts
  • Job offerings
  • RURU

IPHAR (Innovative Pharmacology Research, LLC ) Skolkovo FASIE

IPHAR (Innovative Pharmacology Research, LLC )

  • About us
    • History
    • Advantages
    • IPHAR company group
    • Board of directors
    • Scientific council
  • Investment projects
    • Preclinical stage
    • Clinical stage
    • Information for investors
  • Services
    • Drug development
    • Pharmaceutical technology
    • Pharmaceutical development
    • Preclinical trials
    • Pharmaceutical and
      pharmacokinetic analysis
    • Clinical trials
  • Video
  • Skolkovo Collective Use Center
  • Contacts
  • Job offerings
  • RURU

Интервью с генеральным директором «Ифар» Вениамином Хазановым

09.11.2018No category
Интервью с генеральным директором «Ифар» Вениамином Хазановымadmin2018-11-09T12:50:42+00:00

Интервью с генеральным директором «Ифар» Вениамином Хазановым.

Ссылка: http://www.tvtomsk.ru/tv/russia24/interview_r24/42771-intervyu-veniamin-hazanov-razrabotchik-professor-doktor-medicinskih-nauk.html

Post navigation

← В Томске успешно проходят доклинические испытания препарата для лечения гриппа А
Компания «Протон» получила разрешение на проведение клинических исследований фазы I препарата GRS для лечения заболеваний сердечно-сосудистой системы →

Categories

  • No category
  • Exhibitions
June 2025
M T W T F S S
« May    
 1
2345678
9101112131415
16171819202122
23242526272829
30  

© 2025 IPHAR (Innovative Pharmacology Research, LLC ) All Rights Reserved.